499 related articles for article (PubMed ID: 31372066)
1. Novel approaches to treating advanced systemic mastocytosis.
Gilreath JA; Tchertanov L; Deininger MW
Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
[TBL] [Abstract][Full Text] [Related]
2. Avapritinib for Systemic Mastocytosis.
Bose P; Verstovsek S
Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
[TBL] [Abstract][Full Text] [Related]
3. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
4. Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.
Tashi T; Deininger MW
Immunol Allergy Clin North Am; 2023 Nov; 43(4):723-741. PubMed ID: 37758409
[TBL] [Abstract][Full Text] [Related]
5. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird JH; Gotlib J
Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
[TBL] [Abstract][Full Text] [Related]
6. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic efficacy profiles of avapritinib and nintedanib in
Degenfeld-Schonburg L; Gamperl S; Stefanzl G; Schruef AK; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Peter B; Greiner G; Hadzijusufovic E; Schwaab J; Sperr WR; Hoermann G; Kopanja S; Szépfalusi Z; Hoetzenecker K; Jaksch P; Reiter A; Arock M; Valent P
Am J Cancer Res; 2023; 13(2):355-378. PubMed ID: 36895976
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
[TBL] [Abstract][Full Text] [Related]
9. Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation.
Sandow L; Town A; Heinrich MC
Leuk Res Rep; 2024; 21():100409. PubMed ID: 38273969
[TBL] [Abstract][Full Text] [Related]
10. The Role of Avapritinib for the Treatment of Systemic Mastocytosis.
Sumbly V; Landry I; Iqbal S; Bhatti Z; Alshamam MS; Ashfaq S; Rizzo V
Cureus; 2021 Sep; 13(9):e18385. PubMed ID: 34729266
[TBL] [Abstract][Full Text] [Related]
11. CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in
Schneeweiss-Gleixner M; Filik Y; Stefanzl G; Berger D; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Witzeneder N; Greiner G; Hoermann G; Schiefer AI; Schwaab J; Jawhar M; Reiter A; Sperr WR; Arock M; Valent P; Gleixner KV
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804842
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis.
Akin C
Immunol Allergy Clin North Am; 2023 Nov; 43(4):743-750. PubMed ID: 37758410
[TBL] [Abstract][Full Text] [Related]
13. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
14. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.
Gotlib J; Kluin-Nelemans HC; Akin C; Hartmann K; Valent P; Reiter A
Expert Opin Biol Ther; 2021 Apr; 21(4):487-498. PubMed ID: 33063554
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A; Akin C; Valent P
Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
Akin C; Arock M; Valent P
J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
[TBL] [Abstract][Full Text] [Related]
17. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
18. Precision Medicine in Systemic Mastocytosis.
Nicolosi M; Patriarca A; Andorno A; Mahmoud AM; Gennari A; Boldorini R; Gaidano G; Crisà E
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833353
[TBL] [Abstract][Full Text] [Related]
19. Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.
Piris-Villaespesa M; Alvarez-Twose I
Front Pharmacol; 2020; 11():443. PubMed ID: 32346366
[TBL] [Abstract][Full Text] [Related]
20. Mastocytosis: from a Molecular Point of View.
Komi DEA; Rambasek T; Wöhrl S
Clin Rev Allergy Immunol; 2018 Jun; 54(3):397-411. PubMed ID: 28725969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]